Risk of Herpes Zoster With Janus Kinase Inhibitors Across Disease Indications: A Systematic Review and Network Meta‐Analysis
Dermatologic Therapy · 2025-01 · 2025 (1)
DOI: 10.1155/dth/2928433 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatologic Therapy, online erschienen am 29.12.2025. Verfasst von Yu-Hsiang Lin und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taipei Veterans General Hospital.
Abstract (Originalsprache)
Background
Janus kinase inhibitors (JAKis) have revolutionised the management of immune‐mediated inflammatory diseases (IMIDs); however, their potential to increase the risk of herpes zoster (HZ) remains a major concern.
Methods
A literature search was performed through February 2024. Phase II, III and IV randomised controlled trials (RCTs) and long‐term extension (LTE) studies comparing JAKis with placebo, methotrexate or tumour necrosis factor inhibitors (TNFis) in IMIDs were included. The primary outcome was the risk ratio (RR) for HZ with JAKis compared to placebo/methotrexate or TNFis. Secondary outcomes included incidence rate ratios (IRRs) for HZ comparing JAKis with active treatments during long‐term follow‐up.
Results
A total of 94 RCTs and 30 LTE studies, representing 120,698.3 patient‐years, were included. Pairwise meta‐analysis demonstrated a significantly increased HZ risk with JAKis compared with placebo/methotrexate (RR 1.98, 95% CI 1.56–2.50) and TNFis (RR 2.31, 95% CI 1.73–3.07). Network meta‐analysis identified that in rheumatoid arthritis and psoriatic arthritis, upadacitinib 30 mg significantly increased HZ risk compared with placebo (IRR 2.76, 95% CI 1.58–4.85; IRR 3.54, 95% CI 1.48–8.50) and TNFis (IRR 5.30, 95% CI 3.19–8.81; IRR 10.76, 95% CI 4.78–24.22). In atopic dermatitis, abrocitinib 200 mg was associated with a higher HZ risk compared to placebo (IRR 4.97, 95% CI 1.58–15.60) and dupilumab (IRR 4.85, 95% CI 1.55–15.22). Tofacitinib 10 mg exhibited a higher HZ risk in inflammatory bowel disease compared to placebo (IRR 8.93, 95% CI 1.16–68.53). Patients with atopic dermatitis demonstrated the highest incidence of HZ in both short‐ and long‐term analyses. The risk of HZ was dose‐dependent across all conditions.
Conclusions
JAKi use was significantly associated with an elevated HZ risk in IMIDs, demonstrating a consistent dose–response relationship. These findings emphasise the importance of HZ vaccination before initiating JAKi therapy, particularly for patients on higher doses or long‐term treatment.
Förderung
- National Science and Technology Council
- Taipei Veterans General Hospital
Zitieren
APA
Lin, Y., Wang, Y., Wu, C., Chang, Y., & Chen, C. (2025). Risk of Herpes Zoster With Janus Kinase Inhibitors Across Disease Indications: A Systematic Review and Network Meta‐Analysis. Dermatologic Therapy, 2025(1). https://doi.org/10.1155/dth/2928433
Vancouver
Lin Y, Wang Y, Wu C, Chang Y, Chen C. Risk of Herpes Zoster With Janus Kinase Inhibitors Across Disease Indications: A Systematic Review and Network Meta‐Analysis. Dermatologic Therapy. 2025;2025(1). doi:10.1155/dth/2928433
BibTeX
@article{Lin2025,
author = {Lin, Yu-Hsiang and Wang, Yu-Ching and Wu, Chen-Yi and Chang, Yun-Ting and Chen, Chih-Chiang},
title = {Risk of Herpes Zoster With Janus Kinase Inhibitors Across Disease Indications: A Systematic Review and Network Meta‐Analysis},
journal = {Dermatologic Therapy},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/dth/2928433}
}
EUVIMED